EGFR and non-small cell lung carcinoma: With limited effective therapeutic options in TKI‐resistant NSCLC, these pre‐clinical data offer compelling evidence for the fatty acid metabolism pathway as a candidate target for therapeutic intervention in tyrosine kinase inhibitors resistant EGFR mutant NSCLC.